Bringing Together Global Expertise to Advance Uro-Oncology

Bringing Together Global Expertise to Advance Uro-Oncology

2025.11.24
During the 2025 ESMO Congress, the first and only ESMO-authorized “ESMO China Focus” Uro-Oncology Session was successfully held on October 19 in Berlin. The forum highlighted major advances in urothelial carcinoma and prostate cancer, bringing together Chinese and international experts for in-depth academic discussions and intellectual exchange. Experts agreed that data from landmark studies such as EV-302 and EV-103 firmly establish enfortumab vedotin (EV)–based combination therapy as the new first-line standard of care for locally advanced or metastatic urothelial carcinoma (La/mUC). In addition, androgen-receptor pathway inhibitors (ARPI), represented by enzalutamide—which remains the only ARPI with 8-year overall-survival follow-up—continue to redefine long-term survival expectations for patients with prostate cancer, marking a new era for uro-oncology.
When the breeze rises over West Lake and wisdom sends ripples across the world, when the Qiantang tide surges and innovation breaks waves toward a new era— the 2025 International Cell and Immunotherapy Congress officially opens 

When the breeze rises over West Lake and wisdom sends ripples across the world, when the Qiantang tide surges and innovation breaks waves toward a new era— the 2025 International Cell and Immunotherapy Congress officially opens 

2025.11.21
On November 14, 2025, the Second International Cell and Immunotherapy Congress convened in Hangzhou. The meeting is co-chaired by He Huang from the First Affiliated Hospital of Zhejiang University School of Medicine and Mohamad Mohty, President of the International Academy for Clinical Hematology (IACH). Clinical experts, basic researchers, young scientists, and representatives from biopharmaceutical enterprises gathered from around the globe to engage in in-depth discussions on the latest advances in cell and immunotherapy. The congress not only showcased cutting-edge scientific achievements but also fostered meaningful interdisciplinary collaboration, illuminating key directions for future innovation in cell therapy, immunotherapy, and hematologic research. Oncology Frontier – Hematology Frontier Update has compiled highlights from the first day of the conference to share this academic event with colleagues and explore new frontiers in the field together.
Prof. Chunrui Li: The Leap from Target Innovation to Clinical Breakthroughs in CAR-T Therapy for Multiple Myeloma

Prof. Chunrui Li: The Leap from Target Innovation to Clinical Breakthroughs in CAR-T Therapy for Multiple Myeloma

2025.11.19
To promote innovation in China’s cell and immunotherapy landscape, facilitate in-depth exchange on key scientific questions, share the latest clinical research progress, and strengthen global collaboration and clinical translation, the 2025 International Cell & Immunotherapy Congress (CTI 2025)—jointly organized by Zhejiang University, the International Academy for Clinical Hematology (IACH), the Zhejiang Society of Immunology, and the Zhejiang Anti-Cancer Association, and co-hosted by the First Affiliated Hospital of Zhejiang University School of Medicine and the Liangzhu Laboratory—was held in Hangzhou from November 13 to 16, 2025.
Professor Ye Xiongjun: From Systemic Therapy to Minimally Invasive Surgery — What “Surprises” Await in Kidney Cancer Treatment?

Professor Ye Xiongjun: From Systemic Therapy to Minimally Invasive Surgery — What “Surprises” Await in Kidney Cancer Treatment?

2025.11.19
In recent years, the incidence of urological malignancies in China has risen steadily. Prostate, bladder, and kidney cancers now rank among the most common malignancies in the country, posing a serious threat to public health. The Department of Urology at the National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences (CICAMS), has long been dedicated to the diagnosis and treatment of urological tumors. With extensive experience in laparoscopic and minimally invasive surgery as well as multidisciplinary cancer management, it stands as a leading force in China’s field of urologic oncology.
NCCU 2025 | Professor Yong Zhang Explains the Advantages, Beneficiaries, and Learning Path of the “Xing’s Neobladder” Technique

NCCU 2025 | Professor Yong Zhang Explains the Advantages, Beneficiaries, and Learning Path of the “Xing’s Neobladder” Technique

2025.11.18
Bladder cancer is one of the most common malignancies of the urinary system. Radical cystectomy remains one of the standard treatments, and urinary diversion is a crucial component of this complex procedure.Professor Xing Nianzeng and his team pioneered a novel laparoscopic-friendly orthotopic ileal neobladder reconstruction technique, known as the “Xing’s Neobladder.” This innovative approach utilizes a detubularized ileal segment to construct a spherical, orthotopic ileal neobladder with two peristaltic input loops, preventing urinary reflux and avoiding excessive tension or compression on the left ureter. The design helps preserve upper urinary tract function while ensuring physiological urine flow.During the National Cancer Center Urological Oncology Conference & Medical Frontier Forum (NCCU 2025), Oncology Frontier – Urology Frontier invited Professor  Yong Zhang from the National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, to share his insights on this groundbreaking technique.